Diamyd Medical - Developing therapies for type 1 diabetes

Production Scientist with GMP experience

We welcome candidates with relevant life science experience to join our team.

Apply

Press Releases

November 26, 2020

Bulletin from Annual General Meeting of Diamyd Medical AB

Events & Mediawatch

November 26, 2020 Sweden

Videopresentation i samband med årsstämma

Calendar

	Dates for financial information and other events
	January 20, 2021 Quarterly Report I Quarterly Report 1 2020/2021
	March 31, 2021 Quarterly Report II Quarterly Report 2 2020/2021
	June 23, 2021 Quarterly Report III Quarterly Report 3 2020/2021
	October 6, 2021 Year-End Report Year-End Report 2020/2021

Company Presentation

Download PDF

Our data support the therapeutic targeting of individuals that carry the specific HLA genes that associate with the therapeutic antigen, in this case HLA DR3-DQ2 and GAD. This paves the way for a precision medicine approach in type 1 diabetes for the diabetes vaccine Diamyd^®.

Ulf Hannelius
President and CEO, Diamyd Medical AB

Diamyd Medical develops therapies for type 1 diabetes
The share is listed on Nasdaq First North Growth Market (ticker: DMYD B)

Read more

Diabetes

10-20% of the more than 463 million living with diabetes suffer from the autoimmune form of the disease, where the immune system destroys the insulin-producing cells. Preserving the insulin producing ability may decrease the risk of complications among patients with autoimmune diabetes by 60-80 percent.
Read more

Products

The antigen-specific immunotherapy Diamyd^® and the regenerative and immunomodulatory therapy Remygen^® are two novel disease-modifying drugs in clinical development phase, aiming to preserve and regenerate the patients’ own insulin production.
Read more

Clinical Trials

The efficacy of intralymphatic administration of Diamyd^® on preserving the insulin producing ability in type 1 diabetes is being confirmed in the Phase IIb trial DIAGNODE-2. The safety and efficacy of Remygen^® on stimulating growth of insulin producing cells in type 1 diabetes is being evaluated for the first time in the Phase I/II trial ReGenerate-1.

Order GAD for preclinical research

ORDER

Share This Page

GAD PRODUCTS

Order GAD for preclinical research

Developing therapies

for type 1 diabetes

Intralymphatic immunotherapy

with Diamyd^®

Production Scientist with GMP experience

Press Releases

Events & Mediawatch

Calendar

Financial Reports

Company Presentation

THE COMPANY

Diamyd Medical develops therapies for type 1 diabetes
The share is listed on Nasdaq First North Growth Market (ticker: DMYD B)

Diabetes

Products

Clinical Trials

Order GAD for preclinical research

ORDER

Annual Report

Contact Us

Subscribe

Follow Us

Developing therapies

for type 1 diabetes

Intralymphatic immunotherapy

with Diamyd®

Production Scientist with GMP experience

Calendar

Company Presentation

THE COMPANY

Diamyd Medical develops therapies for type 1 diabetesThe share is listed on Nasdaq First North Growth Market (ticker: DMYD B)

Order GAD for preclinical research

Annual Report

Follow Us

with Diamyd^®

Diamyd Medical develops therapies for type 1 diabetes
The share is listed on Nasdaq First North Growth Market (ticker: DMYD B)